Powered by: Motilal Oswal
2026-11-17 11:14:08 am | Source: Choice Institutional Equities Ltd
Research Desk What Our Analysts Think November 17, 2026 by Choice Institutional Equities
Research Desk What Our Analysts Think November 17, 2026 by Choice Institutional Equities

1. Q2FY27 Nifty 50 Earnings Wrap-up – Our Equity Strategy team says Nifty 50 companies outside financials grew revenue 24.1% YoY and PAT 27.6% in Q2FY27, with revenue beating consensus by 6.3% and EBITDA by 8.1%. PAT missed consensus by 3.4% on one-offs at Sun Pharma and Dr. Reddys and losses at Tata Motors Passenger Vehicle. FY27E/FY28E consensus net profit was upgraded 1.5%/0.3%, led by Reliance Industries, ONGC, JSW Steel, BSE, ICICI and Kotak, while Maruti Suzuki, Ultratech Cement and ITC saw downgrades. They believe demand has not yet been hit by the prolonged geopolitical conflict, with one-offs holding net income back.

 

2. Q2FY27 Pharmaceuticals Results Review – Our Pharmaceuticals team says coverage companies grew revenue an average 9.2% YoY in Q2FY27, in the mid-teens once exceptional factors are excluded, while average EBITDA margin contracted 140 bps on competition after loss of exclusivity and higher scale-up and R&D spend. Divi's Labs, Laurus Labs and Marksans Pharma led growth. H2FY27E launches including Advair, Saroglitazar and Apixaban should offset US pricing pressure, and biosimilars such as Nivolumab, Aflibercept and Denosumab should contribute from FY28E. They stay positive on the sector, seeing peptides, biosimilars and CDMO as the next growth drivers beyond base generics, and prefer Senores Pharma and Granules India.

 

3. Ashok Leyland: Q2FY27 Result Update – Our Auto and Auto Ancillaries team says Ashok Leyland expects double-digit, potentially mid-teens, FY27 medium and heavy commercial vehicle growth, with replacement demand and market-share gains behind a 34.0% YoY rise in domestic CV volumes. It launched air-suspension trucks and began building a 4 GWh battery-pack facility, while Switch Mobility's e-bus order book reached 2,800 units. EBITDA margin of 10.1% trailed their 10.5% estimate on commodity inflation, and the Hinduja Leyland Finance merger won approval, though auditors flagged loan-balance discrepancies. They see Ashok Leyland as well-positioned for replacement demand, premiumisation and EV opportunities, though commodity costs and West Asia export disruptions remain margin risks. Rating: BUY | TP: 195

 

4. Astra Microwave: Q2FY27 Result Update – Our Defence team says Astra Microwave won an INR 18,440 Mn HAL order for the Uttam AESA radar programme, adding multi-year revenue visibility as indigenous radar, electronic warfare and proprietary systems ramp up. Management guides FY27 revenue of INR 13,000–13,500 Mn with an INR 20,000 Mn aspiration for FY29, and Q2FY27 EBITDA margin of 33.4% beat their estimate. They remain positive on improving execution and the expanding order pipeline, but see current valuations already pricing in a significant part of the growth. Rating: REDUCE | TP: 1,700

 

5. Fineotex Chemical: Q2FY27 Result Update – Our SMIDs team says Fineotex Chemical is building a US water and wastewater treatment business for data centres, semiconductor fabs and advanced industrial facilities, has signed NDAs with several Fortune 500 corporates and expects first orders in Q4FY27E. Gross margin fell ~600 bps QoQ on an unfavourable mix and price pass-through lags, but cost control held EBITDA in line with estimates, while CCT was flat on lumpy order execution. They expect better cost pass-through and rising CCT profitability to improve margins over the next few quarters. Rating: ADD | TP: 57

 

6. Rishabh Instruments: Q2FY27 Result Update – Our Power team says Rishabh Instruments' electrical and electronic instruments (EEI) segment grew 24.9% YoY on new customer wins in Poland and strong US sales, while high-pressure die-casting (HPDC) shrank as the company chose profitability over volume. Management targets 20–25% FY27 EEI growth and HPDC breakeven in FY27, and EBITDA margin of 15.2% missed their estimate on product mix. They see the medium-term outlook for electrical measurement and instrumentation as favourable, supported by electrification, data centres, renewables and grid investment. Rating: BUY | TP: 815

 

For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer

SEBI Registration no.: INZ 000160131

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here